Open AccessClinical Trial Data as Public Goods: Fair Trade and the Virtual Knowledge Bank as a Solution to the Free Rider Problem - A Framework for the Promotion of Innovation by Facilitation of Clinical Trial Data Sharing among Biopharmaceutical Companies in the Era of Omics and Big Data
Author(s) -
Nikolaos Evangelatos,
Matthias Reumann,
Hans Lehrach,
Angela Brand
Publication year - 2016
Publication title -
public health genomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 51
eISSN - 1662-8063
pISSN - 1662-4246
DOI - 10.1159/000446101
Subject(s) - data sharing , clinical trial , promotion (chess) , business , knowledge sharing , knowledge management , medicine , computer science , political science , alternative medicine , pathology , politics , law
Knowledge in the era of Omics and Big Data has been increasingly conceptualized as a public good. Sharing of de-identified patient data has been advocated as a means to increase confidence and public trust in the results of clinical trials. On the other hand, research has shown that the current research and development model of the biopharmaceutical industry has reached its innovation capacity. In response to that, the biopharmaceutical industry has adopted open innovation practices, with sharing of clinical trial data being among the most interesting ones. However, due to the free rider problem, clinical trial data sharing among biopharmaceutical companies could undermine their innovativeness.